Aileron Therapeutics, Inc. (ALRN)

NASDAQ: ALRN · IEX Real-Time Price · USD
2.980
-0.200 (-6.29%)
At close: Jul 15, 2024, 4:00 PM
2.990
+0.010 (0.34%)
After-hours: Jul 15, 2024, 7:21 PM EDT
-6.29%
Market Cap 64.41M
Revenue (ttm) n/a
Net Income (ttm) -18.07M
Shares Out 21.61M
EPS (ttm) -3.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 95,820
Open 3.150
Previous Close 3.180
Day's Range 2.770 - 3.200
52-Week Range 1.010 - 7.420
Beta 2.22
Analysts Strong Buy
Price Target 19.00 (+537.58%)
Earnings Date Aug 9, 2024

About ALRN

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 29, 2017
Employees 15
Stock Exchange NASDAQ
Ticker Symbol ALRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ALRN stock is "Strong Buy" and the 12-month stock price forecast is $19.0.

Price Target
$19.0
(537.58% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aileron Therapeutics to be Included in the Russell Microcap® Index

AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

14 days ago - PRNewsWire

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated

2 months ago - GlobeNewsWire

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address sig...

2 months ago - GlobeNewsWire

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes in...

2 months ago - GlobeNewsWire

Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes in...

2 months ago - GlobeNewsWire

Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a ...

2 months ago - GlobeNewsWire

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 202...

3 months ago - GlobeNewsWire

Aileron Therapeutics Announces CEO Transition

Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class medi...

4 months ago - GlobeNewsWire

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

Topline results from Phase 1b study of LTI-03, Aileron's novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 Topl...

5 months ago - GlobeNewsWire

Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

Panel discussion will highlight LTI-03, Aileron's novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis Panel discussion will highlight LTI-03, Aileron's novel Caveolin-...

5 months ago - GlobeNewsWire

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF...

9 months ago - PRNewsWire

Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mu...

1 year ago - GlobeNewsWire

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

1 year ago - GlobeNewsWire

Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split

Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022 Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022

1 year ago - GlobeNewsWire

Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

1 year ago - GlobeNewsWire

Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patien...

1 year ago - GlobeNewsWire

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

BOSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patie...

1 year ago - GlobeNewsWire

Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patie...

1 year ago - GlobeNewsWire

Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patie...

2 years ago - GlobeNewsWire

Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

2 years ago - GlobeNewsWire

Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

2 years ago - GlobeNewsWire

Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

2 years ago - GlobeNewsWire

Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting

Aileron Therapeutics (NASDAQ: ALRN) announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated non-small cell lung cancer (NSCLC) undergoing treatment with fi...

2 years ago - Benzinga

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

BOSTON, June 29, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

2 years ago - GlobeNewsWire

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patient...

2 years ago - GlobeNewsWire